Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
DNDN > SEC Filings for DNDN > Form 8-K on 13-Jan-2014All Recent SEC Filings

Show all filings for DENDREON CORP



Change in Directors or Principal Officers

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

(b) On January 13, 2014, Mark Frohlich, Executive Vice President of Research and Development and Chief Medical Officer, notified Dendreon Corporation (the "Company") that he will be leaving the Company effective February 1, 2014.

Andrew S. Sandler, M.D., has been appointed to Executive Vice President, Chief Medical Officer, and will be the site head of the Company's operations in Seattle, Washington. Dr. Sandler will also join the Executive Committee.

  Add DNDN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for DNDN - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.